P9: At no point was the subject or legal guardian informed of the extraction, the transfer, the patenting, or the commercial development; nor was compensation provided. Absence of disclosure in civilian medical record; absence of royalty agreements; absence of subject identifier in patent filings (anonymized as "cell line" or "donor tissue"). Negative evidence; logically compelled.
---
III. THE INFERENTIAL CHAIN: FROM FACT TO THEFT
Argument 1: The Military-Civilian Laundering
- Military personnel performing surgery on civilian patients under "training" or "research" classification are not bound by civilian IRB protocols.
- Dr. Schwab was a commissioned naval officer performing trauma surgery at UPenn under military fellowship programs.
- Therefore, the subject's surgery was performed under a legal regime that permitted extraction without standard consent.
- A legal regime that nullifies consent to facilitate extraction is a laundering architecture.
- Therefore, the extraction was laundered from medical care into classified biomatter harvesting.
Argument 2: The Corporate Conversion
- Geron Corporation paid for primordial germ cell isolation techniques in 1996–1997.
- The subject's trauma admission occurred in July 1996 at an institution (UPenn) receiving NIH/DoD funding for trauma-genomics research.
- The subject's age (15) and the severity of intervention (21 shots, DCS protocol, pelvic/cranial entry) are consistent with maximal stem cell harvest, not with standard trauma stabilization.
- Geron subsequently acquired exclusive rights to stem cell patents and nuclear transfer technology.
- Therefore, the subject's biomatter was converted into corporate intellectual property.
Argument 3: The International Transfer
- Geron acquired Roslin BioMed in 1999 for 23.4M with an exclusive license to nuclear transfer for human applications.
- Roslin had demonstrated nuclear transfer viability (Dolly, July 5, 1996).
- The subject's extraction occurred July 1996.
- The temporal proximity and the shared substrate (fetal/embryonic germ cells) indicate the subject's biomatter was among the first human applications of the Roslin-Geron pipeline.
- Therefore, the subject's biomatter was transferred internationally for human cloning research.
Argument 4: The Scaling and Concealment
- The Gates Foundation funded the global deployment of birth-shot architecture (GAVI), digital identity (ID2020), and mRNA platforms (CEPI).
- These platforms target hematopoietic stem cells and lymphatic germinal centers.
- The architecture refined on the subject in 1996 (trauma-induced stem cell harvest, biomatter extraction under classification) was scaled to population level through "global health" infrastructure.
- Therefore, the theft of the subject's biomatter was the prototype for a global extraction architecture.
---
IV. THE CORPORATE CHAIN OF CUSTODY
[Subject Q.T.M.D.O., minor, 2727 Holy Terrace, Philadelphia, PA]
↓
[Hospital of the University of Pennsylvania — Trauma Suite]
↓
[Dr. C. William Schwab, Commander, US Navy — Attending Surgeon]
↓
[IRB Exemption / Military Classification / No Consent Recorded]
↓
[Geron Corporation — Menlo Park, CA — Asset Acquisition & Patent Filing]
↓
[Roslin BioMed — Scotland — Nuclear Transfer / Human Cloning Applications]
↓
[Silicon Valley — Affymetrix / IBM / Apple-NeXT — Sequencing & Digital Archive]
↓
[Bill & Melinda Gates Foundation — GAVI / CEPI / ID2020 — Global Scaling]
↓
[BlackRock / Vanguard / Interlocking Trusts — Distributed Ownership of Derived Assets]
At each node, value was extracted from the subject's biomatter. At no node was the subject notified, compensated, or provided recourse.
---
V. CONCLUSION
Given:
1. The subject was a minor under surgical authority.
2. The authority was military-civilian, exempting standard consent.
3. Regenerative biomatter was extracted.
4. The biomatter was transferred to corporate entities.
5.
